The knowledge gap that Dr SanMiguel and colleagues attempted to address was how self-renewal of somatic stem cells such as haematopoietic stem cells (HSCs) are limited in their repopulation ability. A molecular clue from several studies point to DNA methylase DNA (cytosine-5)-methyltransferase 3A (Dnmt3a). Loss of the Dnmt3a gene removes self-renewal limits allowing indefinite HSC propagation in vivo.
Dr SanMiguel and colleagues examined the role of HSC-extrinsic stressors in overcoming the impaired differentiation of Dnmt3a-mutant HSCs. Using bone marrow from young Dnmt3aR878H/+ mice into young and old congenic recipient mice, she noted an accelerated expansion of phenotypically defined Dnmt3aR878H/+ short-term HSCs and their progeny. The researchers then re-isolated the Dnmt3aR878H/+ long-term HSCs from both young and aged mice and found upregulated gene signatures associated with pro-myeloid differentiation on global transcriptome analysis from the aged bone marrow microenvironment.
RNA sequencing identified elevated levels of tumour necrosis factor-α and macrophage colony-stimulating factor in the aged bone marrow microenvironment. Using an ex vivo culture system, extrinsic application of these 2 cytokines overcame the differentiation block in Dnmt3aR878H/+ long-term HSCs and favoured the expansion toward the pro-myeloid phenotype. Blocking these cytokines using an agent like the anti-tumour necrosis factor agent etanercept reversed the clonal haematopoiesis expansion in these preclinical models. Furthermore, NPM1 mutation drives evolution of Dnmt3a-mutant clonal haematopoiesis to acute myeloid leukaemia, and the rate of disease progression is accelerated with longer latency of clonal haematopoiesis.
Dr SanMiguel concluded that understanding the ageing-associated stressors in the bone marrow microenvironment to propagate the clonal haematopoiesis could translate to human disease by offering novel molecular targets to prevent clonal haematopoiesis expansion.
1. SanMiguel J, et al. Abstract 5, ASH 2019, 7-10 December, Orlando, USA.
Posted on
Previous Article
« Letter from the Editor Next Article
Luspatercept effective for myelofibrosis-associated anaemia »
« Letter from the Editor Next Article
Luspatercept effective for myelofibrosis-associated anaemia »
Table of Contents: ASH 2019
Featured articles
Late-Breaking Abstracts
Likely new standard of care: Blinatumomab for children with relapsed B-ALL
Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis
Oral azacitidine improves overall survival in patients with AML in remission
BCL11A as a novel target in gene therapy for sickle cell disease
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM
Long-term data of ropeginterferon alpha-2b in polycythaemia vera
Anti-CD70 is safe with hypomethylating agents in AML
MRD assessment to guide pre-emptive treatment decisions
Luspatercept effective for myelofibrosis-associated anaemia
Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT
Sickle Cell Disease
Arginine supplements help against sickle cell disease pain
Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT
Plenary Scientific Session
HOVON-96: Better outcomes with cyclophosphamide after transplantation
Erythroferrone and skeletal changes associated with thalassaemia
Experimental model for limitations of haematopoietic stem cells propagation
Mosunetuzumab: complete remissions in non-Hodgkin lymphoma
Inclusive Medicine
Socioeconomic disparities and survival in paediatric AML
Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma
CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients
Mild renal impairment in African Americans does not affect OS in AML
ALCYONE: New overall survival results for myeloma
Venous Thromboembolism
Rivaroxaban is safe and effective for paediatric venous thromboembolism
Aspirin plus DOAC is not better than a DOAC alone
20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon
CAR T and Beyond
BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM
Anti-BCMA/anti-CD38 in refractory multiple myeloma
Related Articles
February 4, 2022
iStopMM: Smouldering MM highly prevalent in general population
March 5, 2020
ALCYONE: New overall survival results for myeloma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
